ImmuCell Corporation
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 10.4m | 11.0m | 13.7m | 15.3m | 19.2m | 18.6m | - |
% growth | - | 5 % | 25 % | 12 % | 25 % | (4 %) | - |
EBITDA | <1m | <1m | (<1m) | (1.4m) | <1m | (2.3m) | - |
% EBITDA margin | 7 % | 1 % | (7 %) | (9 %) | 1 % | (12 %) | - |
Profit | (<1m) | (2.3m) | (1.3m) | (1.0m) | (<1m) | (2.5m) | - |
% profit margin | (2 %) | (21 %) | (9 %) | (7 %) | - | (13 %) | - |
EV / revenue | 5.1x | 4.2x | 2.7x | 3.0x | 3.2x | 2.9x | - |
EV / EBITDA | 77.8x | 519.1x | -38.6x | -33.1x | 241.3x | -23.5x | - |
R&D budget | 2.0m | 3.5m | 3.7m | 4.4m | 4.2m | 4.5m | - |
R&D % of revenue | 20 % | 32 % | 27 % | 28 % | 22 % | 24 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $3.5m | Post IPO Equity | |
$6.5m | Post IPO Debt | ||
$500k | Post IPO Debt | ||
* | N/A | $8.3m | Post IPO Equity |
* | $3.0m | Post IPO Debt | |
Total Funding | - |
Recent News about ImmuCell Corporation
EditImmuCell Corporation is a specialized animal health company focused on improving the health and productivity of dairy and beef industries. The company develops, manufactures, and markets the First Defense product line, which provides immediate protection against aggressive pathogens such as E. coli, coronavirus, and rotavirus in newborn dairy and beef calves. This unique product is derived from colostrum and is the only USDA-accredited scours preventative that does not rely on traditional antibiotics. ImmuCell serves dairy and beef producers, offering cost-effective solutions to maximize the health and welfare of their calves and milk-producing cows. The company operates in the animal health market, adhering to stringent standards set by USDA, CFIA, FDA, and OMRI. ImmuCell's business model revolves around the development and commercialization of its proprietary products, generating revenue through direct sales to its target market. The company prides itself on running a lean operation, focusing on efficacy and customer commitment without inflating prices due to bureaucratic overhead.
Keywords: animal health, dairy industry, beef industry, colostrum-derived, scours prevention, E. coli, coronavirus, rotavirus, USDA-accredited, cost-effective solutions.